文献速递细菌感染、耐药与抗菌药物医院感染防控

多黏菌素治疗患者肾毒性与神经毒性发生率的系统综述

Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins.
PubMed 文献 · Clin Microbiol Infect · 2021-01-06

该系统综述检索了Medline、Embase和Cochrane Library数据库(截至2020年1月2日),纳入237篇报告,分析多黏菌素治疗患者的肾毒性与神经毒性发生率。多黏菌素组总体肾毒性率为0.282(95%CI 0.259-0.307),排除吸入为主或评估方法不合国际标准的研究后为0.391(95%CI 0.364-0.419);与非多黏菌素方案相比肾毒性风险更高(OR 2.23,95%CI 1.58-3.15,p<0.001)。总体神经毒性率为0.030(95%CI 0.020-0.043),与非多黏菌素方案相比无显著差异(p 0.051)。

要点

  • 多黏菌素治疗总体肾毒性率0.282,严格评估标准下为0.391。
  • 多黏菌素肾毒性风险高于非多黏菌素方案(OR 2.23)。
  • 总体神经毒性率0.030,与非多黏菌素方案无显著差异。

核心结论

  • 多黏菌素治疗与非多黏菌素方案相比肾毒性风险更高,神经毒性发生率总体较低且组间无显著差异。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、Embase和Cochrane Library数据库(2020年1月2日),纳入237篇随机对照试验、队列和病例对照研究,多数为单臂观察性研究。
  • 肾毒性分析纳入35,569例接受多黏菌素治疗的患者,采用随机效应模型进行荟萃分析,数据允许时用混合效应模型作亚组分析。

主要发现

  • 多黏菌素治疗患者总体肾毒性率为0.282(95%CI 0.259-0.307)。
  • 排除吸入为主或肾毒性评估未采用RIFLE、KDIGO或AKIN标准的研究后,肾毒性率为0.391(95%CI 0.364-0.419)。
  • 与非多黏菌素方案相比,多黏菌素肾毒性比值比为2.23(95%CI 1.58-3.15),p<0.001。
  • 多黏菌素类型、剂量、患者年龄、合并肾毒性药物数量及利尿剂、糖肽类或血管加压药使用对肾毒性率有显著影响。
  • 多黏菌素治疗总体神经毒性率为0.030(95%CI 0.020-0.043),与非多黏菌素方案相比差异无统计学意义(p 0.051)。

关键数值与推荐

  • 肾毒性评估采用国际公认标准RIFLE、KDIGO或AKIN。
  • 肾毒性合并率0.282(95%CI 0.259-0.307);严格标准下0.391(95%CI 0.364-0.419)。
  • 多黏菌素vs非多黏菌素肾毒性OR 2.23(95%CI 1.58-3.15),p<0.001。
  • 神经毒性合并率0.030(95%CI 0.020-0.043),组间比较p 0.051。

临床怎么用

  • 使用多黏菌素时应重视肾毒性监测,尤其对高龄、合并多种肾毒性药物或使用利尿剂、糖肽类、血管加压药的患者。
  • 神经毒性风险总体较低,但仍需在治疗期间保持临床观察。

局限性

  • 纳入研究多数为单臂观察性研究,可能存在异质性与偏倚。
  • 肾毒性率受吸入用药比例和评估标准不统一影响,排除相关研究后发生率明显升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nephrotoxicity and neurotoxicity are commonly associated with polymyxin treatment; however, the emergence of multidrug-resistant Gram-negative bacteria with limited therapeutic options has resulted in increased use of polymyxins. OBJECTIVES: To determine the rates of nephrotoxicity and neurotoxicity during polymyxin treatment and whether any factors influence these. DATA SOURCES: Medline, Embase and Cochrane Library databases were searched on 2 January 2020. STUDY ELIGIBILITY CRITERIA: Studies reporting nephrotoxicity and/or neurotoxicity rates in patients with infections treated with polymyxins were included. Reviews, meta-analyses and reports not in English were excluded. PARTICIPANTS: Patients hospitalized with infections treated with systemic or inhaled polymyxins were included. For comparative analyses, patients treated with non-polymyxin-based regimens were also included. METHODS: Meta-analyses were performed using a random-effects model; subgroup meta-analyses were conducted where data permitted using a mixed-effects model. RESULTS: In total, 237 reports of randomized controlled trials, cohort and case-control studies were eligible for inclusion; most were single-arm observational studies. Nephrotoxic events in 35,569 patients receiving polymyxins were analysed. Overall nephrotoxicity rate was 0.282 (95% confidence interval (CI) 0.259-0.307). When excluding studies where >50% of patients received inhaled-only polymyxin treatment or nephrotoxicity assessment was by methods other than internationally recognized criteria (RIFLE, KDIGO or AKIN), the nephrotoxicity rate was 0.391 (95% CI 0.364-0.419). The odds of nephrotoxicity were greater with polymyxin therapies compared to non-polymyxin-based regimens (odds ratio 2.23 (95% CI 1.58-3.15); p < 0.001). Meta-analyses showed a significant effect of polymyxin type, dose, patient age, number of concomitant nephrotoxins and use of diuretics, glycopeptides or vasopressors on the rate of nephrotoxicity. Polymyxin therapies were not associated with a significantly different rate of neurotoxicity than non-polymyxin-based regimens (p 0.051). The overall rate of neurotoxicity during polymyxin therapy was 0.030 (95% CI 0.020-0.043). CONCLUSIONS: Polymyxins are associated with a higher risk of nephrotoxicity than non-polymyxin-based regimens.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Wagenlehner F, Lucenteforte E, Pea F, et al. Systematic review on estimated rates of nephrotoxicity and neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 2021. PMID: 33359542. doi:10.1016/j.cmi.2020.12.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。